<DOC>
	<DOC>NCT01416441</DOC>
	<brief_summary>The goal of the current trial is to obtain long term efficacy, safety and tolerability data of Once weekly aripiprazole in children and adolescents with Tourette's Disorder.</brief_summary>
	<brief_title>Safety &amp; Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Completed participation or discontinued due to lack of efficacy at week 5 or later in either Trial 3110272 or 3110273 Written ICF obtained from a legally acceptable representative &amp; informed assent at Baseline as applicable by trial center's IRB/IEC The subject, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator. The subject experienced AEs during the doubleblind trial (3110272 or 3110273) that would, in the investigator's judgment, preclude further exposure to aripiprazole. The subject had protocol violations during the doubleblind trial considered major in the judgment of the investigator which would deem the subject a poor candidate for the trial A positive drug screen at baseline for cocaine, alcohol or other drugs of abuse which will result in early termination at Week 1 Sexually active patients not using 2 approved methods of contraception; breastfeeding or pregnant. Risk of committing suicide Body weight lower than 16 kg Abnormal laboratory test results, vital signs and ECG results</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Tourette's Disorder</keyword>
	<keyword>tic disorders</keyword>
</DOC>